Gilead's IBD drug shows success in mid-stage trial

• Gilead Sciences' pill, emvistegrast, succeeded in a mid-stage trial for bowel disease.
• A 200 milligram daily dose of emvistegrast taken for 12 weeks eliminated symptoms in patients.
• The study reported a 23% placebo-adjusted improvement in symptoms.
• The results could support Gilead's efforts to develop new drugs for inflammatory and autoimmune conditions.
• The trial was conducted over a period of 12 weeks.